Hearts & Minds Blog

What’s Your “Why”?

Tim Mayleben

President and Chief Executive Officer

This past weekend Esperion participated, for the 15th year, in the American Heart Association’s (AHA) annual Heart Walk to raise… more

Posted In: Tim Mayleben

Esperion Investor Day: Lighting the Way for Phase 2b Results

Tim Mayleben

President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day… more

Reflections One Year Post-IPO

Tim Mayleben

President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million… more

Posted In: Company News

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density… more

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than… more